WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1994026774) NOVEL TREATMENTS FOR ALLERGIC DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1994/026774    International Application No.:    PCT/US1994/005632
Publication Date: 24.11.1994 International Filing Date: 19.05.1994
Chapter 2 Demand Filed:    08.12.1994    
IPC:
A61K 38/00 (2006.01), C07K 14/415 (2006.01)
Applicants: CYTEL CORPORATION [US/US]; 3525 John Hopkins Court, San Diego, CA 92121 (US)
Inventors: ALEXANDER, Jeff; (US).
FRANCO, Alessandra; (US).
GREY, Howard, M.; (US).
SETTE, Alessandro, D.; (US)
Agent: BASTIAN, Kevin, L.; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th floor, One Market Plaza, San Francisco, CA 94105 (US)
Priority Data:
08/064,298 19.05.1993 US
Title (EN) NOVEL TREATMENTS FOR ALLERGIC DISEASES
(FR) NOUVEAUX TRAITEMENTS DE MALADIES ALLERGIQUES
Abstract: front page image
(EN)The present invention provides novel peptides for treating allergic diseases such as celiac disease. The peptides bind MHC glycoproteins associated with celiac disease and block T cell activation associated with the disease. The peptides may block MHC-antigenic peptide complex formation. Alternatively, the peptides may be T cell antagonist peptides and form inhibitory complexes which competitively inhibit binding between MHC-antigenic peptide complexes which induce activation of T cells associated with celiac disease. Methods for identifying peptides of the present invention are also disclosed.
(FR)La présente invention concerne de nouveaux peptides utilisés dans le traitement de maladies allergiques, telles que la maladie c÷liaque. Les peptides fixent les glycoprotéines du complexe majeur d'histocompatibilité (MHC) associées à la maladie c÷liaque et bloquent l'activation des lymphocytes T associés à cette maladie. Les peptides peuvent bloquer la formation de complexes peptidiques antigéniques de MHC. Dans une autre variante, les peptides peuvent être des peptides antagonistes des lymphocytes T et peuvent former des complexes inhibiteurs qui inhibent de manière compétitive la liaison entre des complexes peptidiques antigéniques de MHC qui induisent l'activation des lymphocytes T associés à la maladie c÷liaque. La présente invention concerne également des procédés d'identification de ces peptides.
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)